Montana AI Healthcare Regulations: A Compliance Guide

Quick Answer: AI Healthcare Regulation in Montana

Montana lacks dedicated, comprehensive AI healthcare legislation. Providers, developers, and health systems deploying AI tools in Montana must comply with federal regulatory frameworks, existing Montana state healthcare statutes, and professional conduct rules enforced by Montana licensing boards.

The practical result: an AI-powered diagnostic tool used by a Montana physician must satisfy FDA requirements for Software as a Medical Device, comply with HIPAA data handling rules, conform to Montana's health information confidentiality statutes under Montana Code Annotated (MCA) Title 50, Chapter 16, and meet the professional standards the Montana Board of Medical Examiners enforces under MCA Title 37. None of these frameworks were written with AI specifically in mind, but all apply.

Montana has not, as of this writing, enacted a standalone AI-in-healthcare statute or established a formal state AI task force with binding authority over healthcare. Providers should monitor the Montana Legislature and the Montana Department of Public Health and Human Services (DPHHS) for emerging guidance, but the current compliance map is built on existing law.

Federal Regulatory Landscape for AI in Healthcare

Montana entities must comply with federal regulations. Key agencies include:

FDA: Software as a Medical Device

The FDA regulates AI and machine learning tools that meet the definition of Software as a Medical Device (SaMD). This means software that performs a medical purpose without being part of a hardware device. The governing framework is in 21 CFR Parts 800 through 898 (medical device regulations). The FDA has also issued specific guidance documents that apply directly to AI tools.

Key FDA guidance documents for Montana developers and providers include:

• "Clinical Decision Support Software" (final guidance, 2022): defines which software functions are regulated as devices and which are exempt.
• "Artificial Intelligence and Machine Learning (AI/ML)-Based Software as a Medical Device Action Plan" (2021): outlines the FDA's iterative approach to regulating adaptive AI algorithms.
• "Marketing Submission Recommendations for a Predetermined Change Control Plan for AI/ML-Enabled Device Software Functions" (2024 draft guidance): addresses how manufacturers can pre-authorize algorithm updates without a new 510(k) each time.

A cross-sectional analysis of FDA-authorized oncology AI devices found that clinical evidence supporting authorization varied substantially across device types (Litt H et al., Journal of Cancer Policy, 2026, PubMed ID 42025919). That variability matters for Montana providers evaluating vendor claims: FDA authorization does not automatically mean the tool performs reliably in your patient population.

Pre-market authorization pathways (510(k), De Novo, PMA) and post-market surveillance obligations under 21 CFR Part 822 apply to any Montana facility that manufactures or modifies a regulated AI device. If deploying a vendor's cleared device without modification, the manufacturer holds the primary regulatory burden, but Business Associate Agreement and clinical oversight obligations remain with the deploying entity.

HIPAA: Protected Health Information in AI Systems

Any AI system that processes Protected Health Information (PHI) triggers HIPAA obligations under 45 CFR Parts 160, 162, and 164. The Privacy Rule (45 CFR Part 164, Subpart E) and Security Rule (45 CFR Part 164, Subpart C) govern how PHI can be used to train, validate, or run AI models.

Common compliance oversights in AI deployments include:

First, if a vendor's AI system touches PHI, that vendor is a Business Associate under 45 CFR §164.502(e). A signed Business Associate Agreement is mandatory before PHI flows to the system. This includes cloud-based AI platforms, third-party diagnostic tools, and any AI-assisted coding or documentation software.

Second, de-identification of training data must meet the standards in 45 CFR §164.514(b), either the Expert Determination method or the Safe Harbor method. Partial de-identification is not de-identification under HIPAA.

FTC: Consumer Protection and Algorithmic Bias

The Federal Trade Commission has authority over deceptive and unfair practices under 15 U.S.C. §45. In healthcare AI, this translates to scrutiny of vendor marketing claims, algorithmic bias that causes discriminatory outcomes, and data practices that harm consumers. Montana providers relying on vendor AI tools should review vendor claims against actual clinical evidence. The FTC has taken enforcement action against health technology companies for unsubstantiated efficacy claims, and that risk flows downstream to deploying organizations that repeat those claims to patients.

ONC: Interoperability and Health IT Certification

The Office of the National Coordinator for Health Information Technology sets certification standards for health IT under 45 CFR Part 170. AI tools integrated into certified Electronic Health Record systems must comply with interoperability requirements, including those related to information blocking (45 CFR Part 171). Montana providers using AI features embedded in EHR platforms should confirm those features do not create information blocking scenarios when sharing patient data.